U.S. Markets closed

AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

Daniel Collins
AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.